Loading
A phase 3 trial testing Cetrelimab in bladder & urothelial cancer, active and no longer recruiting.
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder is a phase 3 interventional study registered as NCT04658862, led by Janssen Research & Development, and active but no longer recruiting on the registry. Official title: A Phase 3, Multi-centre, Randomised Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy. Planned enrolment is 518 participants (actual). The study started in 2020-12-07 and primary completion is expected in 2026-12-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cetrelimab, Johnson & Johnson, Bladder & urothelial cancer.
Shares Cetrelimab, Muscle-invasive and advanced bladder cancer, Johnson & Johnson, Bladder & urothelial cancer.
Shares Cetrelimab, Johnson & Johnson.
Shares Muscle-invasive and advanced bladder cancer, Johnson & Johnson, Bladder & urothelial cancer.
Shares Cetrelimab, Johnson & Johnson.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/